CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »

Positive data reported for eptinezumab in Sunrise trial New insights on treatment holidays with erenumab Dual CGRP ligand mAb and gepant therapy reduces headache severity CGRP-mAb switching yields migraine day reduction Lower switching rates with atogepant than CGRP mAbs EMBRACE shows erenumab reduces migraine severity Older patients benefit from CGRP mAbs too DELIVER shows long term QoL benefits with eptinezumab

Professor Hayrunnisa Bolay

Editorial Board

Professor of Neurology and Algology, Gazi University, Ankara, Turkey

Hayrunnisa Bolay is a Professor of Neurology and Algology, working as a headache specialist at Gazi University in Ankara, Turkey. She is the director of the Neuropsychiatry Center, Neuroscience and Neurotechnology Center, and a member of the Turkish Academy of Sciences. She has been actively involved in clinical and basic headache research particularly related to the pathophysiology of migraine, cortical spreading depression, thalamocortical excitability and multi-sensory disturbances associated with migraine. She has published many scientific papers, authored book chapters, and lectured both nationally and internationally on headache topics, and she has been honoured by awards for headache research.

Professor Bolay participated in the Migraine Working Group for the ICHD III classification. She was a member of the Board of Trustees of the International Headache Society and is a member of the Education Standing Committee.

« Back to Editorial Board

Educational Partners and Supporters

This program is funded in part via an independent educational grant from AbbVie.

Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.

Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2024 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach | Educational Partners and Supporters |